Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.46 |
| ▸ | NPC1 | O15118 | 7/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287937 | 0.85 | RAB9A (0.58) | RAB9AHPGDLMNAKDM4EMAPT | |
| SCHEMBL9911644 | 0.74 | RAB9A (0.60) | RAB9AHPGDLMNAKDM4EMAPT | |
| SCHEMBL508571 | 0.73 | KMT2A (0.61) | RAB9AHPGDLMNAKDM4EMAPT | |
| SCHEMBL15001259 | 0.69 | RAB9A (0.65) | RAB9AHPGDLMNAKDM4EMAPT | |
| SCHEMBL4282948 | 0.69 | MAPT (0.63) | RAB9AHPGDLMNAKDM4EMAPT | |
| SCHEMBL4282973 | 0.68 | RAB9A (0.74) | RAB9AHPGDLMNAKDM4EMAPT | |
| SCHEMBL9911642 | 0.68 | RAB9A (0.67) | RAB9AHPGDLMNAKDM4EMAPT | |
| SCHEMBL619636 | 0.68 | RAB9A (0.62) | RAB9AHPGDLMNAKDM4EMAPT | |
| SCHEMBL4283404 | 0.67 | RAB9A (0.77) | RAB9AHPGDLMNAKDM4EMAPT | |
| SCHEMBL4288841 | 0.67 | S1PR3 (0.67) | RAB9AHPGDLMNATP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404304-B1 | Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same | SIERRA SCIENCES, LLC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250179122-A1 | Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same | SIERRA SCIENCES, LLC | 2025-06-05 | — | — | US | disclosed |
| US-20090143451-A1 | COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME | SIERRA SCIENCES INC. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179122-A1 | Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same | TERT, RNGTT, TERF2 | RAB9A 4044/4885HPGD 1038/4885LMNA 2035/4885 |
| US-12404304-B1 | Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same | TERT, TELO2, POT1 | RAB9A 4662/4885HPGD 1606/4885LMNA 2979/4885 |
| US-20090143451-A1 | COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME | TERT, TERF2, RNMT | RAB9A 3970/4885HPGD 649/4885LMNA 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.